JNJ

171.13

+2.32%↑

NVS

117.8

+2.37%↑

ABT

130.11

+2.14%↑

TMO

467.4

+1%↑

ISRG

483.15

-0.03%↓

JNJ

171.13

+2.32%↑

NVS

117.8

+2.37%↑

ABT

130.11

+2.14%↑

TMO

467.4

+1%↑

ISRG

483.15

-0.03%↓

JNJ

171.13

+2.32%↑

NVS

117.8

+2.37%↑

ABT

130.11

+2.14%↑

TMO

467.4

+1%↑

ISRG

483.15

-0.03%↓

JNJ

171.13

+2.32%↑

NVS

117.8

+2.37%↑

ABT

130.11

+2.14%↑

TMO

467.4

+1%↑

ISRG

483.15

-0.03%↓

JNJ

171.13

+2.32%↑

NVS

117.8

+2.37%↑

ABT

130.11

+2.14%↑

TMO

467.4

+1%↑

ISRG

483.15

-0.03%↓

Search

Merck & Co Inc.

Closed

SectorHealthcare

79.93 0.82

Overview

Share price change

24h

Current

Min

78.42

Max

79.97

Key metrics

By Trading Economics

Income

1.3B

5.1B

Sales

-95M

16B

P/E

Sector Avg

12.218

40.048

EPS

2.22

Dividend yield

3.68

Profit margin

32.745

Employees

73,000

EBITDA

386M

7.3B

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+28.55% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

3.68%

2.45%

Next Earnings

30 Oct 2025

Next Dividend date

7 Oct 2025

Next Ex Dividend date

15 Sept 2025

Market Stats

By TradingEconomics

Market Cap

-1.6B

211B

Previous open

79.11

Previous close

79.93

News Sentiment

By Acuity

33%

67%

109 / 374 Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

Merck & Co Inc. Chart

Past performance is not a reliable indicator of future results.

Related News

29 Jul 2025, 10:45 UTC

Earnings

Merck & Co. to Lay Off Workers, Reduce Real Estate to Invest in New Products

29 Jul 2025, 11:13 UTC

Earnings

Merck Stock Falls After Earnings on Revenue Miss and Job Cuts -- Barrons.com

29 Jul 2025, 10:45 UTC

Earnings

Merck Stock Falls After Earnings on Revenue Miss and Job Cuts -- Barrons.com

29 Jul 2025, 10:30 UTC

Earnings

Merck: Updated FY Adj EPS Outlook Does Not Include Anticipated Impact of Verona Pharma Acquisition >MRK

29 Jul 2025, 10:30 UTC

Earnings

Merck: $200M of Costs Related to Impact of Tariffs in FY Outlook Unchanged Vs Previous Guidance Pending Outcome of Additional Potential Government Actions >MRK

29 Jul 2025, 10:30 UTC

Earnings

Merck: As Part of Initiative, Approved New Restructuring Program in Which Co. Expects to Eliminate Certain Administrative, Sales and R&D Positions >MRK

29 Jul 2025, 10:30 UTC

Earnings

Merck: Updated FY Adj EPS Outlook Includes Revised Negative Impact of Foreign Exchange of About 15c/Shr >MRK

29 Jul 2025, 10:30 UTC

Earnings

Merck: For Latest 2Q, Recorded Charges of $649M Related to Restructuring Program >MRK

29 Jul 2025, 10:30 UTC

Earnings

Merck Narrows FY View To Sales $64.3B-$65.3B Vs Prior View $64.1B-$65.6B >MRK

29 Jul 2025, 10:30 UTC

Earnings

Merck: Expect Actions Under Restructuring Program to Result in Annual Cost Savings of About $1.7B, Which Will Be Substantially Realized by End of 2027 >MRK

29 Jul 2025, 10:30 UTC

Earnings

Merck: Will Continue to Hire Employees Into New Roles Across Strategic Growth Areas of the Business >MRK

29 Jul 2025, 10:30 UTC

Earnings

Merck: Restructuring Program Is Part of the Multiyear Optimization Initiative Expected to Achieve $3B in Annual Cost Savings by End of 2027 >MRK

29 Jul 2025, 10:30 UTC

Earnings

Merck Sees Cumulative Pretax Costs Related to Program to Be About $3B >MRK

29 Jul 2025, 10:30 UTC

Earnings

Merck Launching New Multiyear Optimization Initiative to Enable Transformation of CO's Portfolio by Generating Expected $3B in Annual Cost Savings From Productivity Actions >MRK

29 Jul 2025, 10:30 UTC

Earnings

Merck: Savings Will Be Fully Reinvested to Support New Product Launches and Pipeline Across Multiple Therapeutic Areas >MRK

29 Jul 2025, 10:30 UTC

Earnings

Merck: Will Reduce Global Real-Estate Footprint and Continue to Optimize Manufacturing Network, Aligning Geography of Global Manufacturing to Co's Customers >MRK

29 Jul 2025, 10:30 UTC

Earnings

Merck 2Q Winrevair Sales $336M >MRK

29 Jul 2025, 10:30 UTC

Earnings

Merck 2Q Keytruda Sales Up 9% >MRK

29 Jul 2025, 10:30 UTC

Earnings

Merck: Lower Gardasil/Gardasil 9 and Januvia/Janumet Sales Primarily Due to Lower Demand in China >MRK

29 Jul 2025, 10:30 UTC

Earnings

Merck 2Q Gardasil/Gardasil 9 Sales Down 55% >MRK

29 Jul 2025, 10:30 UTC

Earnings

Merck 2Q Gardasil/Gardasil 9 Sales $1.13B >MRK

29 Jul 2025, 10:30 UTC

Earnings

Merck 2Q Animal Health Sales Up 11% >MRK

29 Jul 2025, 10:30 UTC

Earnings

Merck 2Q Pharmaceutical Sales Down 2% >MRK

29 Jul 2025, 10:30 UTC

Earnings

Merck 2Q Januvia/Janumet Sales Down 1% >MRK

29 Jul 2025, 10:30 UTC

Earnings

Merck 2Q Sales $15.81B >MRK

29 Jul 2025, 10:30 UTC

Earnings

Merck 2Q Pharmaceutical Sales $14.05B >MRK

29 Jul 2025, 10:30 UTC

Earnings

Merck 2Q Animal Health Sales $1.65B >MRK

29 Jul 2025, 10:30 UTC

Earnings

Merck 2Q Keytruda Sales $7.96B >MRK

29 Jul 2025, 10:30 UTC

Earnings

Merck 2Q Animal Health Sales Up 11% >MRK

29 Jul 2025, 10:30 UTC

Earnings

Merck 2Q EPS $1.76 >MRK

Peer Comparison

Price change

Merck & Co Inc. Forecast

Price Target

By TipRanks

28.55% upside

12 Months Forecast

Average 101.93 USD  28.55%

High 141 USD

Low 82 USD

Based on 16 Wall Street analysts offering 12 month price targets forMerck & Co Inc. - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

16 ratings

9

Buy

7

Hold

0

Sell

Technical Score

By Trading Central

76.03 / 83.28Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

109 / 374 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Merck & Co Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.